Ayham Shneker, MD
Internal Medicine · San Antonio, TXNPI 1871557454
Payments from drug & device makers
Across 1,803 payments — averaging $506.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$814K
- Kowa Research Institute, Inc.$59K
- Regeneron$16K
- AbbVie$16K
- Lilly USA, LLC$960
- Novo Nordisk$879
- plus $7K from 54 others
What the payments were for
- Travel & lodging$8757%
- Food & beverage$11,02492%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$913,494 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 383 | $552,156 |
| JardianceEmpagliflozin | 256 | $399,971 |
| TrulicityDulaglutide | 140 | $265,970 |
| MounjaroTirzepatide | 161 | $227,343 |
| FarxigaDapagliflozin Propanediol | 157 | $181,712 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 136 | $165,422 |
| EliquisApixaban | 91 | $112,142 |
| Bydureon BciseExenatide Microspheres | 40 | $94,156 |
| LinzessLinaclotide | 65 | $78,440 |
| JanuviaSitagliptin Phosphate | 49 | $68,367 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $64,091 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $49,001 |
| XareltoRivaroxaban | 38 | $45,893 |
| MyrbetriqMirabegron | 46 | $45,081 |
| ProliaDenosumab | 25 | $43,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $879 | $576,519397 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $960 | $493,313301 claims |
| Boehringer IngelheimJardiance, Tradjenta | $162 | $422,415270 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $425 | $222,749208 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $415 | $194,362178 claims |
| PfizerEliquis | $188 | $112,14291 claims |
| AbbVieLinzess, Vraylar | $15,546 | $101,40579 claims |
| MerckJanuvia, Janumet Xr | $274 | $76,99860 claims |
| Johnson & JohnsonXarelto | $218 | $45,89338 claims |
| Astellas Pharma US IncMyrbetriq | $283 | $45,08146 claims |
| AmgenProlia | $784 | $43,65825 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $140 | $40,46243 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in San Antonio
- Robert BassSan Antonio$25.6M
- Hernan SalazarSan Antonio$18.5M
- Dennis RuffSan Antonio$7.5M
- Cassandra KeySan Antonio$5.6M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.